bavituximab humanmouse chimeric monoclonal antibody phosphatidylserine component cell membranes exposed cell transformed solid tumor cancer cell cells infected hepatitis process cell death highly controlled usually immune response phosphatidylserine bavituximab binds conjugate appears stimulate immune response phosphatidylserine abundant anionic phospholipid cells plasma membrane usually positioned internally however apoptosis several pathological conditions including tumorigenesis infection types viruses phosphatidylserine flipped internal external external potentially recognized antibodies targeting external phosphatidylserine may strategy novel broadspectrum antiviral bavituximab antibody binds complexes phosphatidylserinebinding plasma protein anionic phospholipids laboratory experiments treatment bavituximab found rescue mice otherwise lethal infections mouse cytomegalovirus cmv pichinde virus model lassa fever virus proposed mechanisms therapeutic effect included bavituximab directly clearing infectious virus bloodstream induction antibodydependent cellular cytotoxicity virusinfected cells bavituximab inhibited replication influenza preliminary experiments chicken bavituximab invented university texas southwestern medical center dallas peregrine pharmaceuticals exclusively licensed intellectual property related bavituximab university including us patent invented alan j schroit us patents invented laboratory philip e january bavituximab phase iii clinical trial nonsmall cell lung cancer phase iiiii trial breast cancer phase ii trial pancreatic cancer phase iii trial hepatocellular carcinoma phase clinical trials malignant melanoma rectal cancer development discontinued influenza prostate phase ii trial hepatitis results reported phase iii sunrise trial nsclc discontinued early analysis interim peregrine changed business focus contract manufacturing changed name avid bioservices end february sold bavituximab drug assets oncologie httpsenwikipediaorgwikibavituximab